{"name": "RXi Pharmaceuticals",
 "permalink": "rxi-pharmaceuticals",
 "crunchbase_url": "http://www.crunchbase.com/company/rxi-pharmaceuticals",
 "homepage_url": "http://www.rxipharma.com/",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "admin@RXiPharma.com",
 "phone_number": "508-767-3861",
 "description": "",
 "created_at": "Wed Mar 02 10:56:22 UTC 2011",
 "updated_at": "Mon Jun 03 11:22:40 UTC 2013",
 "overview": "\u003Cp\u003ERXi Pharmaceuticals Corporation is a discovery-stage biopharmaceutical company pursuing therapeutics based on ribonucleic acid (RNA) interference (RNAi). RNAi therapeutic platform includes two components: Novel RNAi Compounds and Advanced Delivery Technologies. The Company has developed a number of forms of rxRNA compounds. These RNAi compounds include rxRNAori, rxRNAsolo and sd-rxRNA, or self delivering RNA. The suite of delivery technologies is comprised of delivery vehicles, which could be combined with various rxRNA compounds, as well as sd-rxRNA compounds, which are chemically modified and have the property of entering cells and tissues to effect silencing without the need for any additional delivery vehicle. \u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       35],
      "assets/images/resized/0012/4572/124572v1-max-150x150.png"],
     [[250,
       58],
      "assets/images/resized/0012/4572/124572v1-max-250x250.png"],
     [[255,
       60],
      "assets/images/resized/0012/4572/124572v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President and Chief Executive Officer",
    "person":
     {"first_name": "Geert",
      "last_name": "Cauwenbergh",
      "permalink": "geert-cauwenbergh",
      "image":
       {"available_sizes":
         [[[100,
            114],
           "assets/images/resized/0013/0816/130816v1-max-150x150.jpg"],
          [[100,
            114],
           "assets/images/resized/0013/0816/130816v1-max-250x250.jpg"],
          [[100,
            114],
           "assets/images/resized/0013/0816/130816v1-max-450x450.jpg"]],
        "attribution": ""}}},
   {"is_past": true,
    "title": "President and CEO",
    "person":
     {"first_name": "Noah",
      "last_name": "D. Beerman",
      "permalink": "noah-d-beerman",
      "image": null}},
   {"is_past": true,
    "title": "Director, President and CEO",
    "person":
     {"first_name": "Mark",
      "last_name": "Ahn",
      "permalink": "mark-ahn",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$23.9M",
 "funding_rounds":
  [{"round_code": "grant",
    "source_url": "http://www.masshightech.com/stories/2012/10/01/daily50-RXi-gets-300K-SBIR-grant-for-retinal-cancer-therapy.html",
    "source_description": "RXi gets $300K SBIR grant for retinal cancer therapy",
    "raised_amount": 300000.0,
    "raised_currency_code": "USD",
    "funded_year": 2012,
    "funded_month": 10,
    "funded_day": 5,
    "investments":
     [{"company": null,
       "financial_org":
        {"name": "National Cancer Institute",
         "permalink": "national-cancer-institute",
         "image":
          {"available_sizes":
            [[[150,
               26],
              "assets/images/resized/0027/2598/272598v1-max-150x150.png"],
             [[250,
               44],
              "assets/images/resized/0027/2598/272598v1-max-250x250.png"],
             [[287,
               51],
              "assets/images/resized/0027/2598/272598v1-max-450x450.png"]],
           "attribution": null}},
       "person": null}]},
   {"round_code": "private_equity",
    "source_url": "http://www.sec.gov/Archives/edgar/data/1533040/000155133313000051/xslFormDX01/primary_doc.xml",
    "source_description": "SEC",
    "raised_amount": 23628750.0,
    "raised_currency_code": "USD",
    "funded_year": 2013,
    "funded_month": 3,
    "funded_day": 26,
    "investments":
     []}],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [{"price_amount": 7000000.0,
    "price_currency_code": "USD",
    "term_code": null,
    "source_url": "http://www.masshightech.com/stories/2011/03/28/daily42-RXi-buying-Apthera-for-7M-getting-late-stage-drug.html",
    "source_description": "RXi buying Apthera for $7M, getting late-stage drug",
    "acquired_year": 2011,
    "acquired_month": 3,
    "acquired_day": 31,
    "company":
     {"name": "Apthera",
      "permalink": "apthera",
      "image":
       {"available_sizes":
         [[[130,
            49],
           "assets/images/resized/0012/8719/128719v1-max-150x150.jpg"],
          [[130,
            49],
           "assets/images/resized/0012/8719/128719v1-max-250x250.jpg"],
          [[130,
            49],
           "assets/images/resized/0012/8719/128719v1-max-450x450.jpg"]],
        "attribution": null}}}],
 "offices":
  [{"description": "",
    "address1": "60 Prescott Street",
    "address2": "",
    "zip_code": "01605",
    "city": "Worcester",
    "state_code": "MA",
    "country_code": "USA",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [{"description": "RXi raising $8.1M from public equities sale",
    "stoned_year": 2011,
    "stoned_month": 3,
    "stoned_day": 1,
    "source_url": "http://www.masshightech.com/stories/2011/02/28/daily19-RXi-raising-81M-from-public-equities-sale.html",
    "source_text": "",
    "source_description": "RXi raising $8.1M from public equities sale",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "RXi Pharmaceuticals",
      "permalink": "rxi-pharmaceuticals"}},
   {"description": "won a total of almost $580,000 from two Small Business Innovation Research grants awarded through the National Institutes of Health",
    "stoned_year": 2011,
    "stoned_month": 4,
    "stoned_day": 26,
    "source_url": "http://www.masshightech.com/stories/2011/04/25/daily20-RXi-Pharmaceuticals-lands-SBIR-grants-for-RNAi-therapeutics.html",
    "source_text": null,
    "source_description": "RXi Pharmaceuticals lands SBIR grants for RNAi therapeutics",
    "stoneable_type": "Company",
    "stoned_value": null,
    "stoned_value_type": null,
    "stoned_acquirer": null,
    "stoneable":
     {"name": "RXi Pharmaceuticals",
      "permalink": "rxi-pharmaceuticals"}}],
 "ipo":
  {"valuation_amount": null,
   "valuation_currency_code": "USD",
   "pub_year": null,
   "pub_month": null,
   "pub_day": null,
   "stock_symbol": "NASDAQ:RXII"},
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}